ProSomnus (ProSomnus) Cash, Cash Equivalents, Marketable Securities : $3.48 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProSomnus Cash, Cash Equivalents, Marketable Securities?

ProSomnus's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($12.02 Mil) to Dec. 2023 ($6.36 Mil) but then stayed the same from Dec. 2023 ($6.36 Mil) to Mar. 2024 ($3.48 Mil).

ProSomnus's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($1.50 Mil) to Dec. 2022 ($15.92 Mil) but then declined from Dec. 2022 ($15.92 Mil) to Dec. 2023 ($6.36 Mil).

ProSomnus Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for ProSomnus's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProSomnus Cash, Cash Equivalents, Marketable Securities Chart

ProSomnus Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

1.56

1.50

15.92

6.36

ProSomnus Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial								11.56	6.18	12.02	6.36	3.48

ProSomnus Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

ProSomnus (OTCPK:OSAPQ) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

ProSomnus Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of ProSomnus's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

ProSomnus (ProSomnus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ProSomnus Inc (OTCPK:OSAPQ) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

5675 Gibraltar Drive, Pleasanton, CA, USA, 94588

Website

https://www.prosomnus.com

ProSomnus Inc is a medical device manufacturer. It manufacturers precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus's patented devices are more comfortable and less invasive alternative to continuous positive airway pressure therapy, and lead to more effective and patient-preferred outcomes.

Executives

Sung Kim	officer: Chief Technical Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
John Steffens	10 percent owner	C/O DIGITALBRIDGE GROUP, INC., 750 PARK OF COMMERCE DRIVE SUITE 210, BOCCA RATON FL 33487
Gregory P. Ho	10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Brian B Dow	officer: Chief Financial Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Smc Holdings Ii, Lp	10 percent owner	65 EAST 55TH STREET, 33RD FLOOR, NEW YORK NY 10022
Smc Holdings Ii G.p., Llc	10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Laing Rikkers	director	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Len Liptak	director, officer: Chief Executive Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Mark Thomas Murphy	officer: Chief Growth Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Hgp Iii, Llc	10 percent owner	3708 ASHFORD PLACE, GREENVILLE NC 27858
Steven Robert Pacelli	director	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Hmc, Llc	10 percent owner	3708 ASHFORD PLACE, GREENVILLE NC 27858
Healthpointcapital, Llc	10 percent owner	C/O HEALTHPOINTCAPITAL, 505 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Healthpointcapital Partners Iii Lp	10 percent owner	505 Park Avenue, 12th Floor, New York NY 10022
Leonard Hedge	director	7855 BELLA MONTANIA LANE, PALO CEDRO CA 96073